{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:05:46Z","timestamp":1780416346582,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016003","name":"Mie University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical pharmacokinetic data on clazosentan, an endothelin receptor antagonist, after aneurysmal subarachnoid hemorrhage (SAH), particularly data on cerebrospinal fluid (CSF), remain limited. In this study, we evaluated the plasma and CSF concentrations and CSF penetration rate of clazosentan over time, and investigated whether the temporal profile differed between patients with SAH with and without delayed cerebral ischemia (DCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data, plasma, and CSF samples from 37 patients (mean, 63.2\u00a0years) with aneurysmal SAH prospectively collected in the SeCAS registry (nine stroke centers in Mie Prefecture, Japan, 2023\u20132025) were retrospectively analyzed. All patients underwent aneurysm obliteration within 48\u00a0h of SAH onset and were subsequently treated with continuous intravenous clazosentan (10\u00a0mg\/h), with simultaneous collection of plasma and CSF over time. Clazosentan concentrations in plasma and CSF at post-SAH days 0\u20133, 4\u20136, 7\u20139, and 10\u201312 were measured by quantitative liquid chromatography\u2013tandem mass spectrometry, and the CSF penetration rate was calculated. Mixed-effect models for repeated measures were used to assess temporal changes and period-by-DCI interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DCI occurred in seven patients (18.9%). In the overall cohort, plasma clazosentan concentrations decreased over time (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010). CSF concentrations showed no significant temporal change (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.190), whereas the CSF penetration rate increased over time (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The temporal profile of CSF penetration rate differed by DCI status (period-by-DCI interaction,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). In pairwise comparisons, the CSF penetration rate at post-SAH days 10\u201312 was significantly lower in the DCI group (geometric mean ratio 0.3, 95% confidence interval 0.1\u20130.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During continuous intravenous infusion of clazosentan after SAH, plasma clazosentan concentrations declined while CSF concentrations were maintained, resulting in an increased CSF penetration rate. Lower CSF penetration was observed at days 10\u201312 in patients who developed DCI, suggesting a potential association between the relative CSF exposure of clazosentan and DCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-026-02548-6","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:11:58Z","timestamp":1780413118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma and Cerebrospinal Fluid Pharmacokinetics of Clazosentan and its Relationship to Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage"],"prefix":"10.1007","author":[{"given":"Koichi","family":"Hakozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Sekijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8555-5448","authenticated-orcid":false,"given":"Hidenori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SeCAS group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reona","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kanamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotaro","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yume","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujimaro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hatazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nampei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Miya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"3","key":"2548_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12975-020-00867-0","volume":"12","author":"SN Neifert","year":"2021","unstructured":"Neifert SN, Chapman EK, Martini ML, et al. Aneurysmal subarachnoid hemorrhage: the last decade. Transl Stroke Res. 2021;12(3):428\u201346. https:\/\/doi.org\/10.1007\/s12975-020-00867-0.","journal-title":"Transl Stroke Res"},{"issue":"1","key":"2548_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46015-2","volume":"15","author":"S Thilak","year":"2024","unstructured":"Thilak S, Brown P, Whitehouse T, et al. Diagnosis and management of subarachnoid haemorrhage. Nat Commun. 2024;15(1):1850. https:\/\/doi.org\/10.1038\/s41467-024-46015-2.","journal-title":"Nat Commun"},{"issue":"1","key":"2548_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s13054-025-05640-z","volume":"29","author":"KM Busl","year":"2025","unstructured":"Busl KM, Bogossian EG, Claassen J, et al. Beyond the bleed: complications after aneurysmal subarachnoid haemorrhage. Pathophysiology, clinical implications, and management strategies: a review. Crit Care. 2025;29(1):414. https:\/\/doi.org\/10.1186\/s13054-025-05640-z.","journal-title":"Crit Care"},{"issue":"2","key":"2548_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14670\/HH-18-253","volume":"36","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Kanamaru H, Kawakita F, Asada R, Fujimoto M, Shiba M. Cerebrovascular pathophysiology of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Histol Histopathol. 2021;36(2):143\u201358. https:\/\/doi.org\/10.14670\/HH-18-253.","journal-title":"Histol Histopathol"},{"issue":"7","key":"2548_CR5","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2023;54(7):e314\u201370. https:\/\/doi.org\/10.1161\/STR.0000000000000436.","journal-title":"Stroke"},{"issue":"6163","key":"2548_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411\u20135. https:\/\/doi.org\/10.1038\/332411a0.","journal-title":"Nature"},{"issue":"3","key":"2548_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10286-004-0186-y","volume":"14","author":"M Zimmermann","year":"2004","unstructured":"Zimmermann M, Seifert V. Endothelin receptor antagonists and cerebral vasospasm. Clin Auton Res. 2004;14(3):143\u20135. https:\/\/doi.org\/10.1007\/s10286-004-0186-y.","journal-title":"Clin Auton Res"},{"issue":"10","key":"2548_CR8","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1161\/strokeaha.109.560243","volume":"40","author":"A Kramer","year":"2009","unstructured":"Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis. Stroke. 2009;40(10):3403\u20136. https:\/\/doi.org\/10.1161\/strokeaha.109.560243.","journal-title":"Stroke"},{"key":"2548_CR9","doi-asserted-by":"publisher","DOI":"10.2176\/jns-nmc.2025-0185","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Kawabori M, Fujioka Y, et al. Clazosentan affects temporal profile of endothelin-a expression in macro- and microcirculation after subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2025. https:\/\/doi.org\/10.2176\/jns-nmc.2025-0185.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"11","key":"2548_CR10","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/strokeaha.108.519942","volume":"39","author":"RL Macdonald","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015\u201321. https:\/\/doi.org\/10.1161\/strokeaha.108.519942.","journal-title":"Stroke"},{"issue":"7","key":"2548_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/s1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618\u201325. https:\/\/doi.org\/10.1016\/s1474-4422(11)70108-9.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2548_CR12","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/strokeaha.111.648980","volume":"43","author":"RL Macdonald","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E, et al. Randomized trial of Clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463\u20139. https:\/\/doi.org\/10.1161\/strokeaha.111.648980.","journal-title":"Stroke"},{"issue":"1","key":"2548_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3171\/2024.4.JNS232191","volume":"142","author":"SA Mayer","year":"2025","unstructured":"Mayer SA, Bruder N, Citerio G, et al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2025;142(1):98\u2013109. https:\/\/doi.org\/10.3171\/2024.4.JNS232191.","journal-title":"J Neurosurg"},{"issue":"1","key":"2548_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12028-023-01847-6","volume":"40","author":"MM Caylor","year":"2024","unstructured":"Caylor MM, Macdonald RL. Pharmacological prevention of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2024;40(1):159\u201369. https:\/\/doi.org\/10.1007\/s12028-023-01847-6.","journal-title":"Neurocrit Care"},{"key":"2548_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/0271678x251399068","author":"H Sakata","year":"2025","unstructured":"Sakata H, Uchida H, Kanoke A, et al. Stratified assessment of clazosentan efficacy following subarachnoid hemorrhage: a multi-center cohort study. J Cereb Blood Flow Metab. 2025. https:\/\/doi.org\/10.1177\/0271678x251399068.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"2548_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3171\/2022.2.JNS212914","volume":"137","author":"H Endo","year":"2022","unstructured":"Endo H, Hagihara Y, Kimura N, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;137(6):1707\u201317. https:\/\/doi.org\/10.3171\/2022.2.JNS212914.","journal-title":"J Neurosurg"},{"issue":"1","key":"2548_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3171\/jns-07\/07\/0121","volume":"107","author":"H Vatter","year":"2007","unstructured":"Vatter H, Konczalla J, Weidauer S, et al. Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function. J Neurosurg. 2007;107(1):121\u20137. https:\/\/doi.org\/10.3171\/jns-07\/07\/0121.","journal-title":"J Neurosurg"},{"key":"2548_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.wneu.2017.03.062","volume":"102","author":"W Albanna","year":"2017","unstructured":"Albanna W, Weiss M, Conzen C, et al. Systemic and cerebral concentration of nimodipine during established and experimental vasospasm treatment. World Neurosurg. 2017;102:459\u201365. https:\/\/doi.org\/10.1016\/j.wneu.2017.03.062.","journal-title":"World Neurosurg"},{"issue":"5","key":"2548_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/wnf.0000000000000356","volume":"42","author":"R Riva","year":"2019","unstructured":"Riva R, Pegoli M, Contin M, Perrone A, Mohamed S, Zanello M. Cerebrospinal fluid concentrations of nimodipine correlate with long-term outcome in aneurysmal subarachnoid hemorrhage: pilot study. Clin Neuropharmacol. 2019;42(5):157\u201362. https:\/\/doi.org\/10.1097\/wnf.0000000000000356.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"2548_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cpt.3499","volume":"117","author":"MM Moser","year":"2025","unstructured":"Moser MM, R\u00f6ssler K, Hirschmann D, et al. Cerebral ischemia protection after aneurysmal subarachnoid hemorrhage: CSF nimodipine levels after intravenous versus oral nimodipine administration. Clin Pharmacol Ther. 2025;117(2):589\u201397. https:\/\/doi.org\/10.1002\/cpt.3499.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2548_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/strokeaha.116.014250","volume":"48","author":"D H\u00e4nggi","year":"2017","unstructured":"H\u00e4nggi D, Etminan N, Aldrich F, et al. Randomized, open-label, phase 1\/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke. 2017;48(1):145\u201351. https:\/\/doi.org\/10.1161\/strokeaha.116.014250.","journal-title":"Stroke"},{"issue":"4","key":"2548_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1161\/strokeaha.119.027396","volume":"51","author":"AP Carlson","year":"2020","unstructured":"Carlson AP, H\u00e4nggi D, Wong GK, et al. Single-dose intraventricular nimodipine microparticles versus oral nimodipine for aneurysmal subarachnoid hemorrhage. Stroke. 2020;51(4):1142\u20139. https:\/\/doi.org\/10.1161\/strokeaha.119.027396.","journal-title":"Stroke"},{"issue":"10","key":"2548_CR23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/strokeaha.110.589275","volume":"41","author":"MD Vergouwen","year":"2010","unstructured":"Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391\u20135. https:\/\/doi.org\/10.1161\/strokeaha.110.589275.","journal-title":"Stroke"},{"issue":"1","key":"2548_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1227\/01.neu.0000243277.86222.6c","volume":"59","author":"JA Frontera","year":"2006","unstructured":"Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery. 2006;59(1):21\u20137. https:\/\/doi.org\/10.1227\/01.neu.0000243277.86222.6c.","journal-title":"Neurosurgery"},{"key":"2548_CR25","doi-asserted-by":"publisher","DOI":"10.2176\/jns-nmc.2025-0439","author":"H Suzuki","year":"2026","unstructured":"Suzuki H, Akamatsu Y, Abe H, et al. Practical guide to clazosentan administration in patients with aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2026. https:\/\/doi.org\/10.2176\/jns-nmc.2025-0439.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"4","key":"2548_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-014-1647-4","volume":"70","author":"J Zisowsky","year":"2014","unstructured":"Zisowsky J, Fuseau E, Bruderer S, Krause A, Dingemanse J. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK\/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 2014;70(4):409\u201319. https:\/\/doi.org\/10.1007\/s00228-014-1647-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2548_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.hest.2023.10.006","volume":"5","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Nakajima H, Ichikawa T, et al. Beneficial effects of clazosentan add-on treatment on delayed cerebral microcirculatory disturbances after aneurysmal subarachnoid hemorrhage. Brain Hemorrhages. 2024;5(2):62\u20138. https:\/\/doi.org\/10.1016\/j.hest.2023.10.006.","journal-title":"Brain Hemorrhages"},{"key":"2548_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.brainres.2011.03.068","volume":"1392","author":"G Chen","year":"2011","unstructured":"Chen G, Tariq A, Ai J, et al. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats. Brain Res. 2011;1392:132\u20139. https:\/\/doi.org\/10.1016\/j.brainres.2011.03.068.","journal-title":"Brain Res"},{"issue":"3","key":"2548_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/strokeaha.117.020028","volume":"49","author":"H Liu","year":"2018","unstructured":"Liu H, Dienel A, Sch\u00f6ller K, et al. Microvasospasms after experimental subarachnoid hemorrhage do not depend on endothelin A receptors. Stroke. 2018;49(3):693\u20139. https:\/\/doi.org\/10.1161\/strokeaha.117.020028.","journal-title":"Stroke"},{"issue":"1","key":"2548_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0006-8993(98)00817-8","volume":"809","author":"M Sato","year":"1998","unstructured":"Sato M, Noble LJ. Involvement of the endothelin receptor subtype A in neuronal pathogenesis after traumatic brain injury. Brain Res. 1998;809(1):39\u201349. https:\/\/doi.org\/10.1016\/s0006-8993(98)00817-8.","journal-title":"Brain Res"},{"issue":"2","key":"2548_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/(sici)1096-9861(19971215)389:2<348::aid-cne11>3.0.co;2-h","volume":"389","author":"K Kurokawa","year":"1997","unstructured":"Kurokawa K, Yamada H, Ochi J. Topographical distribution of neurons containing endothelin type A receptor in the rat brain. J Comp Neurol. 1997;389(2):348\u201360. https:\/\/doi.org\/10.1002\/(sici)1096-9861(19971215)389:2%3c348::aid-cne11%3e3.0.co;2-h.","journal-title":"J Comp Neurol"},{"issue":"2","key":"2548_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchemneu.2003.12.002","volume":"27","author":"V Naidoo","year":"2004","unstructured":"Naidoo V, Naidoo S, Mahabeer R, Raidoo DM. Cellular distribution of the endothelin system in the human brain. J Chem Neuroanat. 2004;27(2):87\u201398. https:\/\/doi.org\/10.1016\/j.jchemneu.2003.12.002.","journal-title":"J Chem Neuroanat"},{"issue":"3","key":"2548_CR33","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuroscience.2010.01.018","volume":"168","author":"S Kallakuri","year":"2010","unstructured":"Kallakuri S, Kreipke CW, Schafer PC, Schafer SM, Rafols JA. Brain cellular localization of endothelin receptors A and B in a rodent model of diffuse traumatic brain injury. Neuroscience. 2010;168(3):820\u201330. https:\/\/doi.org\/10.1016\/j.neuroscience.2010.01.018.","journal-title":"Neuroscience"},{"issue":"1\u22123","key":"2548_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.regpep.2009.06.004","volume":"158","author":"M Mencarelli","year":"2009","unstructured":"Mencarelli M, Pecorelli A, Carbotti P, Valacchi G, Grasso G, Muscettola M. Endothelin receptor A expression in human inflammatory cells. Regul Pept. 2009;158(1\u22123):1\u20135. https:\/\/doi.org\/10.1016\/j.regpep.2009.06.004.","journal-title":"Regul Pept"},{"issue":"2","key":"2548_CR35","first-page":"241","volume":"51","author":"J Jo\u015bko","year":"2000","unstructured":"Jo\u015bko J, Hendryk S, Jedrzejowska-Szypu\u0142ka H, et al. Effect of endothelin-1 receptor antagonist BQ-123 on basilar artery diameter after subarachnoid hemorrhage (SAH) in rats. J Physiol Pharmacol. 2000;51(2):241\u20139.","journal-title":"J Physiol Pharmacol"},{"issue":"7112","key":"2548_CR36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nature05193","volume":"443","author":"CM Peppiatt","year":"2006","unstructured":"Peppiatt CM, Howarth C, Mobbs P, Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature. 2006;443(7112):700\u20134. https:\/\/doi.org\/10.1038\/nature05193.","journal-title":"Nature"},{"issue":"7494","key":"2548_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13165","volume":"508","author":"CN Hall","year":"2014","unstructured":"Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508(7494):55\u201360. https:\/\/doi.org\/10.1038\/nature13165.","journal-title":"Nature"},{"issue":"5","key":"2548_CR38","doi-asserted-by":"publisher","first-page":"e00380","DOI":"10.1016\/j.neurot.2024.e00380","volume":"21","author":"Y Li","year":"2024","unstructured":"Li Y, Zhou L, Deng H, et al. A switch in the pathway of TRPC3-mediated calcium influx into brain pericytes contributes to capillary spasms after subarachnoid hemorrhage. Neurotherapeutics. 2024;21(5):e00380. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00380.","journal-title":"Neurotherapeutics"},{"key":"2548_CR39","doi-asserted-by":"publisher","first-page":"726520","DOI":"10.3389\/fneur.2021.726520","volume":"12","author":"J Pang","year":"2021","unstructured":"Pang J, Wu Y, Peng J, Yang P, Chen L, Jiang Y. Association of pericyte loss with microthrombosis after subarachnoid hemorrhage in ApoE-deficient mice. Front Neurol. 2021;12:726520. https:\/\/doi.org\/10.3389\/fneur.2021.726520.","journal-title":"Front Neurol"},{"issue":"11","key":"2548_CR40","doi-asserted-by":"publisher","first-page":"42742","DOI":"10.31083\/fbl42742","volume":"30","author":"U Drozd","year":"2025","unstructured":"Drozd U, Vechkapova S, Lanshakov D. Pericytes in brain homeostasis: developmental roles and adult functions. Front Biosci (Landmark Ed). 2025;30(11):42742. https:\/\/doi.org\/10.31083\/fbl42742.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"2548_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0196-9781(94)90207-0","volume":"15","author":"G Feuerstein","year":"1994","unstructured":"Feuerstein G, Gu JL, Ohlstein EH, Barone FC, Yue TL. Peptidic endothelin-1 receptor antagonist, BQ-123, and neuroprotection. Peptides. 1994;15(3):467\u20139. https:\/\/doi.org\/10.1016\/0196-9781(94)90207-0.","journal-title":"Peptides"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02548-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-026-02548-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02548-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:12:00Z","timestamp":1780413120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-026-02548-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":41,"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1007\/s12028-026-02548-6","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Suzuki reported personal fees and a research fund from Nxera Pharma outside the submitted work. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of Mie University Hospital (approval number H2023-010).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all patients or their relatives.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}